Overall, the OHTS has provided the ophthalmologist with more predictive diagnostic tools with which to evaluate ocular hypertension patients. An improved ability to identify those patients at ...

China’s National Medical Products Administration (NMPA) has approved the marketing authorisation application of Santen ...

Akums Drugs & Pharmaceuticals Ltd. on Tuesday announced the launch of a pioneering Ripasudil-Timolol combination therapy for ...

Akums launches novel ripasudil+timolol combination for glaucoma and ocular hypertension: Our Bureau, Bengaluru Tuesday, April 1, 2025, 16:40 Hrs [IST] Akums Drugs & Pharmaceutical ...

Kenneth A. Beckman While drops are still a large part of early treatment for glaucoma and ocular hypertension, selective laser trabeculoplasty is on the rise. In 2019, the 3-year results of the ...

Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, ...

Voyager DSLT is uniquely poised to accelerate the adoption of laser as a first-line therapy, unlocking the treatment’s availability ... There were no related ocular serious adverse events ...

Japanese ophthalmology company Santen Pharmaceutical (TYO: 4536) said it has earned approval from Chinese regulatory, the ...

This is basically an intracameral implant that’s currently in Phase 2 for open-angle glaucoma or ocular hypertension ... show it as good as current treatment alternatives (i.e., non-inferiority).

Ophthalmologists must consider the cost-effectiveness of available treatment options for glaucoma ... in patients with open-angle glaucoma or ocular hypertension, according to a poster at the ...

About Ocular Therapeutix ... which is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Follow the Company on its website, LinkedIn ...